This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant
Bone Marrow Transplantation Open Access 13 January 2024
-
High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant
Bone Marrow Transplantation Open Access 21 September 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Aul C, Giagounidis A, Germing U, Ganser A . Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol 2002; 81: 485–497.
Platzbecker U, Mohr B, von Bonin M, Schetelig J, Ehninger G, Bornhauser M . Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. Leukemia 2007; 21: 2384–2385.
Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L et al. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol 2004; 83: 498–503.
Deeg HJ, Shulman HM, Anderson JE, Bryant EM, Gooley TA, Slattery JT et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 2000; 95: 1188–1194.
Kroger N, Zabelina T, Guardiola P, Runde V, Sierra J, Van Bienzen A et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118: 67–73.
Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003; 82: 336–342.
Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092–1099.
Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 2006; 37: 1003–1008.
Kerbauy DM, Chyou F, Gooley T, Sorror ML, Scott B, Pagel JM et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 2005; 11: 713–720.
Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008; 14: 246–255.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ocheni, S., Kröger, N., Zabelina, T. et al. Outcome of allo-SCT for chronic myelomonocytic leukemia. Bone Marrow Transplant 43, 659–661 (2009). https://doi.org/10.1038/bmt.2008.366
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.366
This article is cited by
-
EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant
Bone Marrow Transplantation (2024)
-
High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant
Bone Marrow Transplantation (2022)
-
Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update
Current Hematologic Malignancy Reports (2015)
-
Current status of allogeneic HST for chronic myelomonocytic leukemia
Bone Marrow Transplantation (2012)
-
Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience
Bone Marrow Transplantation (2010)